1. Home
  2. POM vs SVRA Comparison

POM vs SVRA Comparison

Compare POM & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POM
  • SVRA
  • Stock Information
  • Founded
  • POM 2015
  • SVRA 2007
  • Country
  • POM China
  • SVRA United States
  • Employees
  • POM N/A
  • SVRA N/A
  • Industry
  • POM Other Specialty Stores
  • SVRA Biotechnology: Pharmaceutical Preparations
  • Sector
  • POM Consumer Discretionary
  • SVRA Health Care
  • Exchange
  • POM Nasdaq
  • SVRA Nasdaq
  • Market Cap
  • POM 640.8M
  • SVRA 527.2M
  • IPO Year
  • POM 2025
  • SVRA N/A
  • Fundamental
  • Price
  • POM $4.31
  • SVRA $6.25
  • Analyst Decision
  • POM
  • SVRA Buy
  • Analyst Count
  • POM 0
  • SVRA 8
  • Target Price
  • POM N/A
  • SVRA $6.88
  • AVG Volume (30 Days)
  • POM 1.3M
  • SVRA 2.1M
  • Earning Date
  • POM 01-01-0001
  • SVRA 11-12-2025
  • Dividend Yield
  • POM N/A
  • SVRA N/A
  • EPS Growth
  • POM N/A
  • SVRA N/A
  • EPS
  • POM N/A
  • SVRA N/A
  • Revenue
  • POM $46,931,528.00
  • SVRA N/A
  • Revenue This Year
  • POM N/A
  • SVRA N/A
  • Revenue Next Year
  • POM N/A
  • SVRA N/A
  • P/E Ratio
  • POM N/A
  • SVRA N/A
  • Revenue Growth
  • POM 12.37
  • SVRA N/A
  • 52 Week Low
  • POM $3.35
  • SVRA $1.89
  • 52 Week High
  • POM $6.43
  • SVRA $6.37
  • Technical
  • Relative Strength Index (RSI)
  • POM N/A
  • SVRA 84.29
  • Support Level
  • POM N/A
  • SVRA $5.09
  • Resistance Level
  • POM N/A
  • SVRA $4.38
  • Average True Range (ATR)
  • POM 0.00
  • SVRA 0.35
  • MACD
  • POM 0.00
  • SVRA 0.15
  • Stochastic Oscillator
  • POM 0.00
  • SVRA 92.16

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Share on Social Networks: